Skip to main content
. 2022 Mar 4;101(5):979–989. doi: 10.1007/s00277-022-04801-2

Fig. 2.

Fig. 2

Survival data: as of November 11, 2020—A OS; as of August 30, 2019—B PFS and C DOR. OS, overall survival; NE, not evaluable; PFS, progression-free survival; DOR, duration of response